L
Le Xu
Researcher at Shanghai Jiao Tong University
Publications - 86
Citations - 1750
Le Xu is an academic researcher from Shanghai Jiao Tong University. The author has contributed to research in topics: Clear cell renal cell carcinoma & Renal cell carcinoma. The author has an hindex of 21, co-authored 72 publications receiving 1182 citations. Previous affiliations of Le Xu include Fudan University & Fudan University Shanghai Medical College.
Papers
More filters
Journal ArticleDOI
Prognostic value of diametrically polarized tumor-associated macrophages in renal cell carcinoma.
TL;DR: Intratumoral balance of diametrically polarized TAMs is a novel independent predictor for survival in patients with clear-cell renal cell carcinoma and might be a promising target of postoperative adjuvant therapy.
Journal ArticleDOI
Tumor-associated Macrophage-derived Interleukin-23 Interlinks Kidney Cancer Glutamine Addiction with Immune Evasion.
Qiang Fu,Le Xu,Yiwei Wang,Qi Jiang,Zheng Liu,Junyu Zhang,Quan Zhou,Han Zeng,Shanyou Tong,Tao Wang,Yangyang Qi,Baoying Hu,Hangcheng Fu,Huyang Xie,Lin Zhou,Yuan Chang,Yu Zhu,Bo Dai,Weijuan Zhang,Jiejie Xu +19 more
TL;DR: It is found that ccRCC tumor cell-intrinsic glutamine metabolism orchestrates immune evasion via interleukin (IL)-23, and IL-23-high patients had significantly poorer survival than IL- 23-low patients, andIL-23 should be considered a therapeutic target in ccR CC, either alone or in combination with immune checkpoint inhibitors.
Journal ArticleDOI
Klotho suppresses tumor progression via inhibiting PI3K/Akt/GSK3β/Snail signaling in renal cell carcinoma
Yu Zhu,Le Xu,Jian-ping Zhang,Wenping Xu,Yujun Liu,Hankun Yin,Tao Lv,Huimin An,Li Liu,Hongyong He,Heng Zhang,Jing Liu,Jiejie Xu,Zongming Lin +13 more
TL;DR: Results indicate Klotho acts as a tumor suppressor by inhibiting PI3K/Akt/GSK3β/Snail signaling, thus suppressing epithelial‐mesenchymal transition and tumor migration and invasion during RCC progression, and might be used as a potential therapy for advanced RCC.
Journal ArticleDOI
Intratumoral TIGIT+ CD8+ T-cell infiltration determines poor prognosis and immune evasion in patients with muscle-invasive bladder cancer.
Zhaopei Liu,Quan Zhou,Zewei Wang,Hongyu Zhang,Han Zeng,Qiuren Huang,Yifan Chen,Wenbin Jiang,Zhiyuan Lin,Yang Qu,Ying Xiong,Qi Bai,Yu Xia,Yiwei Wang,Li Liu,Yu Zhu,Le Xu,Bo Dai,Jianming Guo,Jiajun Wang,Yuan Chang,Weijuan Zhang +21 more
TL;DR: Intratumoral TIGIT+ CD8+ T-cell abundance could serve as an independent prognosticator for clinical outcome and a predictive biomarker for inferior ACT responsiveness.
Journal ArticleDOI
Tumor-infiltrating CD39 + CD8 + T cells determine poor prognosis and immune evasion in clear cell renal cell carcinoma patients
Yu Qi,Yu Xia,Zhiyuan Lin,Yang Qu,Yangyang Qi,Yifan Chen,Quan Zhou,Han Zeng,Jiajun Wang,Yuan Chang,Qi Bai,Yiwei Wang,Yu Zhu,Le Xu,Lingli Chen,Yunyi Kong,Weijuan Zhang,Bo Dai,Li Liu,Jianming Guo,Jiejie Xu +20 more
TL;DR: Analysis of tumor-infiltrating immune cell landscape in the ccRCC revealed the positive correlation between CD39+CD8+ T cells and Tregs and M2-polarized macrophages, and inhibition of CD39 partially restores the anti-tumor function of CD8+, indicating therapeutic benefit of TKIs therapy.